Breaking News

Dalton, Arch Biopartners Ink Drug Development and Mfg. Pact

To provide GMP prep and filling of AB569 into glass vials to support the Phase I trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dalton Pharma Services has entered a drug development and manufacturing agreement with Arch Biopartners, Inc., a Canadian biotechnology firm, to support Arch’s GMP manufacturing campaign for AB569, the company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs. Dalton will provide formulation development, cGMP powder and liquid filling, analytical method development and validation, and quality control release testing.  Dalton will be responsible f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters